Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Vicente Gimeno-Ballester, Javier Mar, Aisling O’Leary, Róisín Adams & Ramón San Miguel. (2017) Cost-effectiveness analysis of therapeutic options for chronic hepatitis C genotype 3 infected patients. Expert Review of Gastroenterology & Hepatology 11:1, pages 85-93.
Read now
Read now
Heather J. McElroy, Stuart K. Roberts, Alex J. Thompson, Peter W. Angus, Sarah Jane McKenna, Emma Warren & Sharon Musgrave. (2017) Medical resource utilization and costs among Australian patients with genotype 1 chronic hepatitis C: results of a retrospective observational study. Journal of Medical Economics 20:1, pages 72-81.
Read now
Read now
Vicente Gimeno-Ballester, Javier Mar & Ramón San Miguel. (2016) Cost–effectiveness analysis of simeprevir with daclatasvir for non-cirrhotic genotype-1b-naïve patients plus chronic hepatitis C. Expert Review of Pharmacoeconomics & Outcomes Research 16:2, pages 285-294.
Read now
Read now
Eric Druyts, Kristian Thorlund & Edward J. Mills. (2014) Letter to the Editor. Journal of Medical Economics 17:7, pages 445-445.
Read now
Read now
Ramón San Miguel, Vicente Gimeno-Ballester & Javier Mar. (2014) Cost-effectiveness of protease inhibitor based regimens for chronic hepatitis C: a systematic review of published literature. Expert Review of Pharmacoeconomics & Outcomes Research 14:3, pages 387-402.
Read now
Read now
Articles from other publishers (20)
Rodolfo Castro, Louise Crathorne, Hugo Perazzo, Julio Silva, Chris Cooper, Jo Varley-Campbell, Daniel Savignon Marinho, Marcela Haasova, Valdilea G. Veloso, Rob Anderson & Chris Hyde. (2018) Cost-effectiveness of diagnostic and therapeutic interventions for chronic hepatitis C: a systematic review of model-based analyses. BMC Medical Research Methodology 18:1.
Crossref
Crossref
Andrew J. Leidner, Harrell W. Chesson, Philip R. Spradling & Scott D. Holmberg. (2016) Assessing the Effect of Potential Reductions in Non-Hepatic Mortality on the Estimated Cost-Effectiveness of Hepatitis C Treatment in Early Stages of Liver Disease. Applied Health Economics and Health Policy 15:1, pages 65-74.
Crossref
Crossref
Sofia Vitor, Rui Tato Marinho, José Gíria & José Velosa. (2016) An observational study of the direct costs related to hospital admissions, mortality and premature death associated with liver disease in Portugal. BMC Research Notes 9:1.
Crossref
Crossref
Roberto Nuño Solinís, Patricia Arratibel Ugarte, Ander Rojo & Yuri Sanchez Gonzalez. (2016) Value of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic Evidence. Infectious Diseases and Therapy 5:4, pages 491-508.
Crossref
Crossref
Jona T. Stahmeyer, Siegbert Rossol, Florian Bert, Klaus H. W. Böker, Harald-Robert Bruch, Christoph Eisenbach, Ralph Link, Christine John, Stefan Mauss, Renate Heyne, Eckart Schott, Heike Pfeiffer-Vornkahl, Dietrich Hüppe & Christian Krauth. (2016) Outcomes and Costs of Treating Hepatitis C Patients in the Era of First Generation Protease Inhibitors – Results from the PAN Study. PLOS ONE 11:7, pages e0159976.
Crossref
Crossref
Jagpreet Chhatwal, Tianhua He & Maria A. Lopez-Olivo. (2016) Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals. PharmacoEconomics 34:6, pages 551-567.
Crossref
Crossref
Bassem Refaat, Adel Galal El-Shemi & Ahmed Mohammed Ashshi. (2015) The effects of pegylated interferon-α and ribavirin on liver and serum concentrations of activin-A and follistatin in normal Wistar rat: a preliminary report. BMC Research Notes 8:1.
Crossref
Crossref
Ramón San Miguel, Vicente Gimeno-Ballester, Antonio Blázquez & Javier Mar. (2015) Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C. Gut 64:8, pages 1277-1288.
Crossref
Crossref
Erik De Clercq. (2015) Development of antiviral drugs for the treatment of hepatitis C at an accelerating pace. Reviews in Medical Virology 25:4, pages 254-267.
Crossref
Crossref
Jona T Stahmeyer, Siegbert Rossol & Christian Krauth. (2015) Outcomes, costs and cost–effectiveness of treating hepatitis C with direct acting antivirals. Journal of Comparative Effectiveness Research 4:3, pages 267-277.
Crossref
Crossref
Katelijne van de Vooren, Alessandro Curto & Livio Garattini. (2014) Pricing of forthcoming therapies for hepatitis C in Europe: beyond cost-effectiveness?. The European Journal of Health Economics 16:4, pages 341-345.
Crossref
Crossref
Joseph A. Boscarino, Mei Lu, Anne C. Moorman, Stuart C. Gordon, Loralee B. Rupp, Philip R. Spradling, Eyasu H. Teshale, Mark A. Schmidt, Vinutha Vijayadeva & Scott D. Holmberg. (2015) Predictors of poor mental and physical health status among patients with chronic hepatitis C infection: The Chronic Hepatitis Cohort Study (CHeCS). Hepatology 61:3, pages 802-811.
Crossref
Crossref
Bassem Refaat, Ahmed Mohamed Ashshi, Adel Galal El-Shemi & Esam Azhar. (2015)
Activins and Follistatin in Chronic Hepatitis C and Its Treatment with Pegylated-Interferon-
α
Based Therapy
. Mediators of Inflammation 2015, pages 1-16.
Crossref
Crossref
Aikaterini Vellopoulou, Michel van Agthoven, Annemarie van der Kolk, Robert J. de Knegt, Gilles Berdeaux, Sandrine Cure, Florence Bianic & Mark Lamotte. (2014) Cost Utility of Telaprevir–PR (Peginterferon–Ribavirin) Versus Boceprevir–PR and Versus PR Alone in Chronic Hepatitis C in The Netherlands. Applied Health Economics and Health Policy 12:6, pages 647-659.
Crossref
Crossref
Kian Bichoupan, Valerie Martel-Laferriere, David Sachs, Michel Ng, Emily A. Schonfeld, Alexis Pappas, James Crismale, Alicia Stivala, Viktoriya Khaitova, Donald Gardenier, Michael Linderman, Ponni V. Perumalswami, Thomas D. Schiano, Joseph A. Odin, Lawrence Liu, Alan J. Moskowitz, Douglas T. Dieterich & Andrea D. Branch. (2014) Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response. Hepatology 60:4, pages 1187-1195.
Crossref
Crossref
S. Saab, S. C. Gordon, H. Park, M. Sulkowski, A. Ahmed & Z. Younossi. (2014) Cost‐effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection. Alimentary Pharmacology & Therapeutics 40:6, pages 657-675.
Crossref
Crossref
Dalibor Novotny, Lucie Roubalova, Kvetoslava Aiglova, Jana Bednarikova & Margita Bartkova. (2014) IL28B genotyping and treatment of HCV infected subjects. Asian Biomedicine 8:4, pages 445-452.
Crossref
Crossref
S. Deuffic-Burban, S. Cossais & Y. Yazdanpanah. (2014) Coût-efficacité et VHC : mise au point. Journal des Anti-infectieux 16:2, pages 50-63.
Crossref
Crossref
Béla Hunyady, Judit Gervain, Gábor Horváth, Mihály Makara, Alajos Pár, Ferenc Szalay, László Telegdy & István Tornai. (2014) Diagnosis, treatment, and follow-up of hepatitis C-virus related liver disease. Hungarian national consensus guideline. Orvosi Hetilap 155:Supplement 2, pages 3-24.
Crossref
Crossref
Bassem Refaat, Adel Galal El-Shemi, Ahmed Mohamed Ashshi & Adnan AlZanbagi. (2014) Serum Activins and Follistatin during the Treatment of Chronic Hepatitis C Genotypes 1 and 4 and Their Correlations with Viral Load and Liver Enzymes: A Preliminary Report. Gastroenterology Research and Practice 2014, pages 1-9.
Crossref
Crossref